<DOC>
	<DOCNO>NCT02687399</DOCNO>
	<brief_summary>The purpose study determine haemostatic efficacy TT-173 , reduce total blood loss associate total knee arthroplasty .</brief_summary>
	<brief_title>Determine Efficacy TT-173 . Reducing Total Blood Loss Associated With Total Knee Arthroplasty ( HESTAT )</brief_title>
	<detailed_description>As TT-173 clear use topical hemostatic agent , propose study investigate safety efficacy TT-173 knee arthroplasty .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>1 . Patients sign informed consent . 2 . Patients affect degenerative osteoarthritis knee undergo primary total knee replacement . 3 . Patients sexes old 18 year . 4 . Female patient childbearing age* permanently sterile , present negative pregnancy test agree use medically accept anti contraceptive method participation study . This include oral , intravaginal , transdermal , injectable implantable hormonal contraceptive , sexual abstinence , bilateral tubal occlusion , intrauterine hormonereleasing system dispositive vasectomy partner . * Includes period menarche become postmenopausal . A woman consider postmenopausal go without period 12 consecutive month . 5 . Patients must haemoglobin concentration â‰¥ 12.5 g/dL selection visit . 1 . Patients affect kind congenital acquire coagulopathies personal history abnormal haemorrhagic episode . 2 . Patients subject knee replacement due rheumatoid seronegative arthritis , infection autoimmune inflammatory cause join degeneration . 3 . Patients subjected revision procedure knee , hemiarthroplasty receive noncemented knee prosthesis . 4 . Subjects affect serious medical condition would compromise clinical outcome hepatic , respiratory , cardiac renal insufficiency , acute infectious disease active cancer . 5 . Subjects know history haematological alteration causative thrombophilia . 6 . Subjects personal history deep vein thrombosis , pulmonary thromboembolism , retinal vascular occlusion multiple abortion . 7 . Subjects know hypersensitivity allergy component drug . 8 . Subjects currently treatment anticoagulant , antiplatelet antifibrinolytic drug . These subject may eligible treatment stop preoperatively accord condition indicate section 9.2 . 9 . Subjects receive treatment ( erythropoietin , iron , folate ) improve preoperative anaemia . 10 . Subjects free give inform consent mentally incapacitated discretion investigator . 11 . Subjects participate participate past three month another clinical trial drug treatment . 12 . Subjects investigator , collaborator , nurse , centre employee person directly relate development protocol . 13 . Subjects pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>knee arthroplasty</keyword>
</DOC>